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In previous work we had shown that GIcNBu (N-butyryl glu- 
cosamine) decreases the inflammation of SCW arthritis and in- 
creases BMD in this model. This investigation explores the effects 
of GIcNBu on bone loss. 
Chronic SCW arthritis was induced in female rats by a single IP 
injection. The Groups studied were: (a) no arthritis, no treatment; 
(b) arthritis, no treatment; (c) arthritis, GIcNBu 20mg/kg/day; (d) 
arthritis, GIcNBu 200mg/kg/day. The removed left tibiae were 
scanned using micro computed tomography to qualitatively and 
quantitatively measure the GIcNBu dosage effects on bone archi- 
tectu re. 
Isosurfaces generated from the scans show progressively less 
bone erosion with increasing dosages of GIcNBu.(Figure). Tra- 
becular bone volume, number and thickness, and subchondral 
plate thickness increased with GIcNBu dosage, so that Group (d) 
was similar to Group (a). Significant increases occurred predom- 
inantly in the lateral epiphysis and the metaphysis of the high 
dose group. The structure model index values decreased sig- 
nificantly (p=0.030) in the metaphysis from the untreated SCW- 
induced group to the high dose group, indicating a less rod-like 
trabecular structure. Strut analysis showed a significant increase 
(p =0.034) in the length of node to node struts from the untreated 
SCW-induced group to the high dose group on the medial side of 
the proximal epiphysis. 
Fig. 1. Isosurfaces of proximal rat tibia (a) No arthritis, no treatment; (b) 
arthritis, no treatment; (c) arthritis + low dose GIcNBu; (d) arthritis + high 
dose GIcNBu. 
The results indicate a dose-dependent increase in bone connec- 
tivity. The metaphyseal bone structure changes suggest that GIc- 
NBu functions systemically. Comparison of the isosurfaces and 
the architectural parameters studied in this investigation demon- 
strate that GIcNBu effectively protects bone from further erosion 
in this model of chronic inflammatory arthritis. 
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Aim of study: In osteoarthritis (OA), the increased subchondral 
bone remodeling is associated with the development of cartilage 
lesions. These changes are related to an altered metabolism of 
the osteoblasts. The aim of this study was to determine the effect 
of chondroitin sulfate on the expression/production of the major 
osteoblast factors involved in the remodeling of human OA sub- 
chondral bone. 
Methods: The effect of chondroitin sulfate (200 i~g/ml) on human 
OA subchondral bone osteoblasts, before and after stimulation 
with vitamin D3 (1,25(OH)2D3; 50 nM), was measured on the ma- 
jor phenotypic factors, alkaline phosphatase, and osteocalcin; on 
the inflammatory mediators, IL-6 and COX-2; and on the bone 
remodeling factors, RANKL and OPG. 
Results: Data showed that the level of alkaline phosphatase ac- 
tivity upon stimulation by vitamin-D3 challenge, was increased by 
a 1.6-fold over basal values. Chondroitin sulfate did not affect 
basal and vitamin D3-induced alkaline phosphatase or osteocal- 
cin release. On the metabolic factors, chondroitin sulfate had no 
significant effect on IL-6, but significantly inhibited either basal 
or vitamin D3-stimulated COX-2. In the presence of vitamin D3, 
chondroitin sulfate upregulated OPG expression and production. 
On the protein level, chondroitin sulfate significantly increased 
OPG in both basal conditions and in the presence of vitamin D3. 
RANKL expression was almost abrogated with chondroitin sul- 
fate under basal conditions. Interestingly, under basal conditions, 
chondroitin sulfate significantly upregulated the expression ratio 
of OPG/RANKL. Vitamin D3 decreased this ratio, but chondroitin 
sulfate in the presence of vitamin D3 reversed this decrease. 
Conclusions: Our data indicate that chondroitin sulfate does not 
appear to overly affect cell integrity or osteoblast phenotypic cell 
markers. However, chondroitin sulfate by increasing the ratio of 
OPG/RANKL could exert a positive effect on OA subchondral 
bone structural changes, indicating a potential direct beneficial 
effect. Indeed, the expression of RANKL is increased in abnor- 
mal osteoblasts, thereby weighting the balance of OPG/RANKL 
toward bone destruction. Consequently, our data are of major sig- 
nificance as it is the ratio OPG/RANKL that dictates the magni- 
tude of osteoclastogenesis. These findings may help explain the 
mechanisms by which this drug could exert its effect on the pro- 
gression of OA structural changes. 
P327 
EFFECT OF SOME ANTHRAQUINONES ON 
TRABECULAR AND SUBCHONDRAL BONE IN AN 
EXPERIMENTAL ANIMAL MODEL 
M Mian 1 , D Benetti 1 , R Aloisi 1 , A Conte 2, G Ronca 1 
11nterdipartimental Centre of Molecular and Clinical Genetics, 
University of Pisa, Pisa, Italy; 2Department of Agricultural 
Sciences, University of Modena and Reggio Emilia, Modena, 
/ta/y 
Aim of the Study: GR373, GR 375, and GR 377 are patented 
anthraquinone derivatives which are active on both cartilage and 
bone. The water soluble GR 373 (anthraquinone 2,6-disulfonic 
